Advice

The marketing authorisation for rosiglitazone (Avandia) has been withdrawn.

The SMC Advice has been removed from the website.

On 23 September2010 the European Medicines Agency’s (EMA) Committee on Medicinal Products for Human Use (CHMP) recommended the suspension of the marketing authorisation for Avandia Avandamet and Avaglim (rosiglitazone) as the benefits no longer outweigh the risks.

www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/09/WC500096996.pdf

Medicine details

Medicine name:
Rosiglitazone (Avandia®)
SMC ID:
91/04
Indication:
Type 2 diabetes mellitus patients for whom metformin is inappropriate
Pharmaceutical company
GlaxoSmithKline UK Ltd
BNF chapter
Endocrine system
Submission type
Full submission
Status
Withdrawn
Date advice published:
08 March 2004